Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical case: idelalisib-induced immunoglobulin flare.
Novak J, Havrda M, Gaherova L, Spicka J, Kozak T. Novak J, et al. Among authors: kozak t. Immunopharmacol Immunotoxicol. 2017 Aug;39(4):251-252. doi: 10.1080/08923973.2017.1318912. Epub 2017 May 19. Immunopharmacol Immunotoxicol. 2017. PMID: 28523957
Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.
Muraro PA, Pasquini M, Atkins HL, Bowen JD, Farge D, Fassas A, Freedman MS, Georges GE, Gualandi F, Hamerschlak N, Havrdova E, Kimiskidis VK, Kozak T, Mancardi GL, Massacesi L, Moraes DA, Nash RA, Pavletic S, Ouyang J, Rovira M, Saiz A, Simoes B, Trnený M, Zhu L, Badoglio M, Zhong X, Sormani MP, Saccardi R; Multiple Sclerosis–Autologous Hematopoietic Stem Cell Transplantation (MS-AHSCT) Long-term Outcomes Study Group. Muraro PA, et al. Among authors: kozak t. JAMA Neurol. 2017 Apr 1;74(4):459-469. doi: 10.1001/jamaneurol.2016.5867. JAMA Neurol. 2017. PMID: 28241268 Free PMC article.
Individually determined dosing of filgrastim after autologous peripheral stem cell transplantation in patients with malignant lymphoma--results of a prospective multicentre controlled trial.
Faber E, Pytlík R, Slabý J, Zapletalová J, Kozák T, Raida L, Papajík T, Zikesová E, Maresová I, Hamouzová M, Indrák K, Trnený M. Faber E, et al. Among authors: kozak t. Eur J Haematol. 2006 Dec;77(6):493-500. doi: 10.1111/j.1600-0609.2006.00741.x. Epub 2006 Oct 17. Eur J Haematol. 2006. PMID: 17042769 Clinical Trial.
Rituximab-induced coagulopathy.
Novak J, Mocikova H, Pavlicek P, Gaherova L, Kozak T. Novak J, et al. Among authors: kozak t. Leuk Lymphoma. 2012 Nov;53(11):2299-301. doi: 10.3109/10428194.2012.682313. Epub 2012 May 16. Leuk Lymphoma. 2012. PMID: 22480246 Review. No abstract available.
Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial.
Pytlík R, Belada D, Kubáčková K, Vášová I, Kozák T, Pirnos J, Bolomská I, Matuška M, Přibylová J, Campr V, Burešová L, Sýkorová A, Berková A, Klener P, Trněný M; Czech Lymphoma Study Group. Pytlík R, et al. Among authors: kozak t. Leuk Lymphoma. 2015 Jan;56(1):57-64. doi: 10.3109/10428194.2014.904509. Epub 2014 Apr 29. Leuk Lymphoma. 2015. PMID: 24628294
138 results